Achievements and Discoveries

XiMo and Aspira Scientific Launch Air-Stable Metathesis Pills

Delivering Nobel-Winning Catalysis Platform for Rapid Pharmaceutical R&D Screening SAN FRANCISCO, Calif., October 13, 2015 /PRNewswire/ -- XiMo AG (Lucerne, Switzerland) and Aspira Scientific, Inc. (Milpitas, California) announced today the launch of air-stable catalyst pills (CatPac’s) for metathesis chemistry. The importance of metathesis chemistry was highlighted by the Nobel Prize awarded in 2005 to the pioneers of this application. This industrially-relevant application has been utilized in the production of valuable chemical entities such as pharmaceuticals, specialty chemicals, and polymers.

The CatPac system was developed by XiMo, an emerging metathesis technology company and utilizes proprietary molybdenum (Mo) and tungsten (W) catalysts. “Our catalysts represent exceptional value to the chemical industry, especially in pharmaceutical development, given the low cost of Mo compared to ruthenium (Ru) (100-fold less expensive), and its high body tolerance (non-toxic as opposed to Ru),” said Douglas C. Günthardt, Chairman of XiMo. “We have made these highly active catalysts more convenient to use for rapid screening by formulating them in an air-stable pill format that we call the CatPac,” added Dr. Georg Fráter, COO of XiMo. “Our catalysts are also available in native form on commercial scale.”

“As a provider of innovative chemistry solutions, we are continuously launching novel tools to enable discovery and development,” commented Dr. John Chan, CEO of Aspira Scientific. “We are very excited to deliver a broad Nobel-winning metathesis platform in a user- and IP-friendly manner which has been lacking in industry for some time.” This latest addition complements well Aspira Scientific’s broad portfolio of cutting-edge tools for drug and material development. Detailed product information for Mo-CatPac catalysts are available at:www.aspirasci.com/metathesis.
About Aspira Scientific, Inc.

Aspira Scientific is a science-centric enterprise dedicated to empowering scientists reach their aspirations in chemical R&D. We achieve this goal through reducing the cost of basic and applied research by offering research products with superior value in terms of price and quality. By leveraging a truly global innovation ecosystem, we also make available a broader set of next-generation enabling tools for chemical synthesis. For organizations with developmental programs, we provide custom production services via “Collaborate Locally. Commercialize Globally.™” model to afford exceptional value in terms of innovation, quality and IP assurance, and cost-efficiency. For more information on realizing your scientific aspirations now and tomorrow, please visit www.aspirasci.com.

13 October 2015

Olefin Metathesis Highlights

loader
Loading blog posts...

Contact

XiMo AG (Headquarter)
Altsagenstrasse 3
CH-6048 Horw/Lucerne
Switzerland

www.ximo-inc.com


Georg Fráter, COO


XiMo Hungary Ltd.,
Graphisoft Park 'DB' Bdg.
Záhony u. 7.
H-1031 Budapest


Levente Ondi, R&D Director,